LDLinlin Dai

Linlin Dai

*This is an algorithmically generated author record based on publicly available information.

Linlin Dai has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    COL11A1 Inhibits Ferroptosis in Pancreatic Cancer by Regulating AKT/Beclin 1 Dependent Autophagy

    by Hui Wang, Shuang Zhi, Zibo Yang, Na Gu, Linlin Dai, Jun Cai, Juan Wang, Dongdong Li

    Background: Collagen type XI alpha 1 (COL11A1) is overexpressed in pancreatic cancer and is often associated with poor survival, chemoresistance, and tumor recurrence. However, the role of COL11A1 in pancreatic cancer remains poorly understood. Methods: We explored the correlation between COL11A1 and overall survival in pancreatic cancer patients using Kaplan-Meier survival analysis and validated COL11A1’s regulatory role in the viability of pancreatic cancer cell line PANC-1 using Cell Counting Kit-8 and colony formation assays. To clarify the underlying mechanisms, we further examined COL11A1’s modulation of ferroptosis and autophagy in PANC-1 cells by western blot, reverse transcription quantitative polymerase chain reaction (RT-qPCR), and immunofluorescence assays. Moreover, autophagy agonist rapamycin, inhibitor 3-methyladenine (3-MA), and AKT/Beclin 1 pathway inhibitors were employed to dissect the regulatory crosstalk between COL11A1, autophagy, and ferroptosis. Results: COL11A1 expression was negatively correlated with pancreatic cancer patients’ survival rate. Its overexpression significantly enhanced the viability and clonogenic capacity of erastin- and rapamycin-treated PANC-1 cells. Our data showed that COL11A1 reduced intracellular iron levels, suppressed reactive oxygen species accumulation, downregulated malondialdehyde and microtubule—associated protein 1 light chain 3—II/I (LC3II/I) expression, while increasing glutathione (GSH), ferritin heavy chain 1 (FTH1) and solute carrier family 7 member 11 (SLC7A11) levels. Furthermore, COL11A1-mediated ferroptosis inhibition was attenuated by the autophagy agonist Rapamycin but enhanced by the inhibitor 3-MA. Notably, COL11A1 promoted AKT and Beclin 1 phosphorylation, and blocking the AKT/Beclin 1 pathway abrogated its ability to suppress autophagy and ferroptosis in pancreatic cancer cells. Conclusions: The study demonstrated that COL11A1 exerts its oncogenic effects by suppressing autophagy via the AKT/Beclin 1 pathway, consequently inhibiting ferroptosis in pancreatic cancer cells. These findings reveal a novel molecular mechanism through which COL11A1 promotes tumor progression and provide a potential therapeutic target for pancreatic cancer treatment.

  • Copper(II) Complexes of Pyrazino [2,3‐F][1,10]Phenanthroline Induce Cuprotosis and Immunogenic Cell Death in Triple‐Negative Breast Cancer

    by Dongdong Li, Hui Wang, Linlin Dai, Cheng Tan, Shuang Zhi, Zibo Yang

    Recently, cuproptosis has garnered tremendous attention in the field of cancer therapy. However, its effectiveness remains limited by the inadequate delivery efficiency of copper ion carriers. In this regard, we have synthesized and characterized four copper(II) complexes of pyrazino [2,3‐f][1,10]phenanthroline. They demonstrated significant inhibitory effects on the proliferation of the selected cell lines. In particular, 4 exhibited more prominent inhibitory effects on the growth of TNBC cells CAL‐51, MDA‐MB‐231, and MDA‐MB‐468, with IC 50 concentrations ranging from 0.52 to 1.56 μM. It disrupted mitochondrial function in tumor cells, promoted the aggregation of DLAT, and decreased the expression levels of the key proteins FDX1, DLAT, and LIAS involved in cuproptosis. Notably, 4 not only induces cuproptosis but also triggers immunogenic cell death, often marked by the release of damage‐associated molecular patterns (DAMPs), such as calreticulin (CRT) and high mobility group box 1 protein (HMGB1). Our study offers a promising approach for cancer therapy based on cuproptosis.


  • Copper complexes suppress stemness, reverse epithelial‐to‐mesenchymal transition progression, and induce apoptosis on triple negative breast cancer

    by Dongdong Li, Linlin Dai, Luyao Wang, Cheng Tan, Jun Cai, Hui Wang, Xiumei Zhao

    Cancer stem cells (CSCs) are a small proportion of tumor cells with great tumorigenicity, self‐renewal ability, and intrinsic resistance to conventional and targeted cancer therapy; thus, targeting CSC is becoming an emerging cancer treatment. In this paper, five novel copper (II) complexes [Cu(OH‐PIP)(Tyr)(H2O)]PF6 (1), [Cu(m‐OH‐PIP)(Gly)]NO3·2.25H2O (2), [Cu(Cl‐PIP)(Gly)Br] (3), [Cu(F‐PIP)(Tyr)Cl] (4), and [Cu(F‐PIP)(Phe)Br] (5) have been synthesized and characterized by infrared spectroscopy and single crystal X‐ray diffraction analysis. All the complexes were screened for their in vitro cytotoxicity activity against a panel of human breast cancer cells (CAL‐51, MDA‐MB‐231, and MCF‐7), human liver cancer cells (HepG 2, SMMC‐7721) and human pancreatic cancer cells (PANC‐1) using MTT assay. They have potential proliferative inhibition for all the tested cancer cell lines, especially the triple‐negative breast cancer (TNBC) CAL‐51 cells are inhibited significantly with IC50 values ranging from 0.11 to 2.35 μM. Cellular functional assays showed that representative complexes 1 and 5 could trigger apoptosis, evidenced by Hoechst 33258 staining, flow cytometry assays, and the alteration of Bax, Bcl‐2, Caspase‐3, and PARP levels. In addition, they dramatically suppressed colony and mammosphere formation, inhibited cancer cell stemness and migration, and reversed epithelial–mesenchymal transition (EMT) progression in CAL‐51 cells, indicating their great potential as anti‐CSC agents for therapy of TNBC.